Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
The most recent EPS for Boston Scientific Corp is $0.8, beating expectations of $0.78.
How did Boston Scientific Corp BSX's revenue perform in the last quarter?
Boston Scientific Corp revenue for the last quarter is $0.8
What is the revenue estimate for Boston Scientific Corp?
According to 28 of Wall street analyst, the revenue estimate of Boston Scientific Corp range from $5.47B to $4.97B
What's the earning quality score for Boston Scientific Corp?
Boston Scientific Corp has a earning quality score of A-/58.576843. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Boston Scientific Corp report earnings?
Boston Scientific Corp next earnings report is expected in 2026-05-05
What are Boston Scientific Corp's expected earnings?
Boston Scientific Corp expected earnings is $5.33B, according to wall-street analysts.
Did Boston Scientific Corp beat earnings expectations?
Boston Scientific Corp recent earnings of $5.28B does not beat expectations.